- Risk Factors for Febrile Neutropenia during Chemotherapy for HIV-Related Lymphoma
-
Park J, Kim TM, Hwang JH, Kim NH, Choe PG, Song KH, Kim ES, Park SW, Kim HB, Kim NJ, Park WB, Oh MD
- KMID: 2157968
- J Korean Med Sci.
- 2012 Dec;27(12):1468-1471.
- doi: 10.3346/jkms.2012.27.12.1468
We evaluated risk factors for neutropenic fever and febrile prolonged neutropenia during vincristine-including chemotherapy to treat HIV-related lymphoma to investigate whether protease inhibitor (PI) treatment is associated with infectious complications... -
- CITED
-
- Close
- SHARE
-
- Close
- Patterns of Neutropenia and Risk Factors for Febrile Neutropenia of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP
-
Choi YW, Jeong SH, Ahn MS, Lee HW, Kang SY, Choi JH, Jin UR, Park JS
- KMID: 2069930
- J Korean Med Sci.
- 2014 Nov;29(11):1493-1500.
- doi: 10.3346/jkms.2014.29.11.1493
Febrile neutropenia (FN) is the major toxicity of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen in the treatment of diffuse large B-cell lymphoma (DLBCL). The prediction of neutropenia... -
- CITED
-
- Close
- SHARE
-
- Close
